US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Psychiatric Times, pharmtech.com, neurologylive.com and Business Wire. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 4h ago.
Quick answers
Why is "US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- FDA Approves Tauklarify for Tau PET Imaging in Alzheimer Disease Medical Professionals Reference · 12h ago
- FDA approves new Alzheimer’s PET imaging agent from Lantheus Radiology Business · 12h ago
- FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease Psychiatric Times · 12h ago
- What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers? pharmtech.com · 12h ago
- FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup neurologylive.com · 12h ago
- Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease Business Wire · 12h ago
- US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment Reuters · 12h ago
Topics
Related trends
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Alzheimer's risk may be 35% lower with common menopause treatment, study finds
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
FDA travels to Mexico a month after linking Taylor Farms to cyclospora outbreak
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Brain autopsies reveal fewer Alzheimer’s signs in woman who took menopause drug
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
FDA assigns highest-risk Class I status for recall of nearly 1.6 million cartons of eggs
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
A nationwide Walmart soup recall sparks alarm as the FDA flags Listeria risk in 29 states.